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Background: Inflammatory and matrix degrading gene variants have been reported to be associated with disc
degeneration. Some of these variants also modulate peripheral pain. This study examines the association of these
genetic variants with radiographic lumbar disc degeneration and changes in pain and disability at long-term after
surgical and cognitive behavioural management.
Methods: 93 unrelated patients with chronic low back pain (CLBP) for duration of >1 year and lumbar disc
degeneration were treated with lumbar fusion or cognitive intervention and exercises. Standardised questionnaires
included the Oswestry Disability Index (ODI) and Visual Analog Score (VAS) for CLBP, were filled in by patients both
at baseline and at 9 years follow-up. Degenerative changes at baseline Magnetic Resonance Imaging and
Computed Tomography scans, were graded as moderate and severe (N=79). Yield and quality of blood and saliva
DNA was assessed by nano drop spectrophotometry. Eight SNPs in 5 inflammatory and matrix degrading genes
were successfully genotyped. Single marker and haplotype association with severity of degeneration, number of
discs involved, changes in ODI and VAS CLBP, was done using Haploview, linear regression and R-package
Haplostats.
Results: Association analysis of individual SNPs revealed association of IL18RAP polymorphism rs1420100 with
severe degeneration (p = 0.05) and more than one degenerated disc (p = 0.02). From the same gene two SNPs,
rs917997 and rs1420106, were found to be in strong linkage disequilibrium (LD) and were associated with post
treatment improvement in disability (p = 0.02). Haplotype association analysis of 5 SNPs spanning across IL18RAP,
IL18R1 and IL1A genes revealed significant associations with improvement in disability (p=0.02) and reduction in
pain (p=0.04). An association was found between MMP3 polymorphism rs72520913 and improvement in pain
(p = 0.03) and with severe degeneration (p = 0.006).
Conclusions: The findings of the current study suggest a role of variation at inflammatory and matrix degrading
genes with severity of lumbar disc degeneration, pain and disability.* Correspondence: ahmad.omair@ous-hf.no
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Fifty percent report to have back pain yearly in Norway
[1]. Degeneration of the lumbar intervertebral disc is
regarded as a common cause of chronic low back pain
(CLBP) [2]. The etiology of lumbar disc degeneration
(LDD) is complex and not fully explained. LDD is con-
sidered to be a multifactorial disorder involving nu-
merous genetic and environmental factors and their
interactions. Heavy physical loading, trauma, bending,
twisting, prolonged non-neutral work postures, vibra-
tions during vehicle driving, cigarette smoking have been
suggested to be associated with disc degeneration [3,4].
The pathogenesis of LDD involves the degradation of
the normal disc matrix into a disorganized fibrous and
less cartilaginous disc, progressing to the formation of
clefts and fissures and ultimately compromising the disc
integrity [5]. Magnetic Resonance Imaging (MRI) studies
have established a strong heritability of degenerative
changes among twins [6] and genes related to the struc-
tural proteins of the discs (aggrecan and collagens), in-
flammation and matrix degradation have been reported
to be associated with the pathologic and radiographic
changes of LDD [7-10].
The correlation between severity of degeneration and
clinical symptoms is not strong and recent studies
reported no correlation between changes in degene-
rated disc and changes in treatment [11,12].Variants of
some genes coding for inflammatory mediators: inter-
leukin 1A (IL1A); interleukin 18 receptor 1 (IL18R1);
interleukin 18 receptor accessory protein (IL18RAP);
cyclooxygenase 2 (COX2) and matrix metalloprotease 3
(MMP3), have all been found to be associated with dif-
ferent phenotypes of LDD [9,10,13-16]. They have also
been reported to be involved in peripheral modula-
tion of pain [17]. These genes are candidates for assess-
ment of their association with degeneration, pain and
disability.
Pro inflammatory cytokines are involved in extracellu-
lar matrix degradation and fibrosis of the disc, and play
a role in peripheral neuropathic pain. IL1 causes degen-
eration by regulating the destruction of disc matrix by
activating degradative enzymes and inhibiting resyn-
thesis of proteoglycans. It also modulates pain by indu-
cing prostaglandin E2 (PGE2) synthesis which in turn
enhances the activity of phospholipase A2 and COX2.
IL1 secreted by herniated discs, along with IL6 and
TNF-α sensitize the nociceptors that innervate the disc
[18,19]. IL18 is another proinflammatory cytokine that
shares many biological, structural and functional proper-
ties with IL1 [20] and mediates its function through its
receptor IL18R (IL18R1 and IL18RAP). It exerts its pro-
inflammatory effects by inducing the production of
IL-1β, TNF-α, chemokines, nitric oxide and prostaglan-
dins [21,22].MMP3 (stromelysin 1) mediates degeneration of the
disc by degradation of matrix proteoglycans and colla-
gens [23] and also contributes to neuropathic pain after
peripheral nerve injury [24]. MMP3 gene polymorphism
5A/6A (rs72520913) regulates the MMP3 gene expres-
sion with 5A allele possessing twice the promoter acti-
vity than 6A [25].
The COX2 gene (PTGS2) may be involved in disc her-
niation through the up regulation of PGE2 [26]. It is also
reported to be involved in the peripheral modulation of
pain [17,27].
Associations between inflammatory and matrix de-
grading gene variants and changes in long- term pain
and disability after surgical and cognitive behavioural
management, have to our knowledge not been investi-
gated previously. The aim of the present study was to
examine these associations. We also analyzed the yield
and purity of DNA acquired from both blood and saliva
in our patients, in light of an increase in use of saliva as
a source of genomic DNA for genetic association stud-
ies, compared to the blood [28].
Methods
Study design
The cohort was from a randomized control trial, and a
prospective design was used for obtaining clinical data at
long term follow-up and was in the current study used
for genetic association analyses.
Patient sample
124 unrelated Norwegian patients with chronic LBP
recruited from two previously published randomized
control trials [29-32] were invited to participate. At
baseline each patient was examined by at least one spine
surgeon and one specialist in physical and rehabilitation
medicine. The inclusion criteria were: age 25-60 years;
LBP with duration >1 year despite of undergoing super-
vised non-operative treatment; Oswestry disability index
(ODI) score > 30 of 100 points; and disc degeneration at
one or two levels i.e. L4-L5 and/or L5-S1 as assessed by
plain radiography. Exclusion criteria were: widespread
myofascial pain; spinal stenosis with reduced walking
distance and associated neurological signs; recurrent disc
herniation or lateral recess stenosis with clinical signs
of rediculopathy; inflammatory disease; previous spinal
fracture; previous surgical fusion of spine; pelvic pain;
generalized disc degeneration on plain radiographic as-
sessment; ongoing serious somatic or psychiatric disease
that could exclude treatment alternatives; registered
medical abuse and reluctance in accepting either one or
both treatment modalities of this study.
Ninety nine patients responded to the follow up exa-
mination at median 9 years (range 7-11 years). Ninety
three patients (35 males and 58 females) were ethnically
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non-European ethnicity. Out of the 93 patients, 51 were
randomized to lumbar instrumented postero-lateral fu-
sion with transpendicular screws at L4-L5 and /or L5-S1
and 42 to cognitive intervention and exercises given by
physiotherapists and a specialist in physical and reha-
bilitation medicine. This intervention involved one week
plus two weeks at outpatient facility interrupted by two
weeks at home. Five patients randomized to fusion did
not undergo surgery and 14 patients randomized to cog-
nitive treatment had later undergone fusion.
The eligible patients were informed orally as well as in
writing about the study procedures before consenting. The
Regional Committee for Medical Research Ethics in Health
Region South-East Norway approved the study. It was also
recommended by the Biobank Register at Norwegian Insti-
tute of Public Health and by the patient’s ombudsman at,
Oslo University hospital.
Outcome variables of pain and disability
The clinical data regarding age, ethnicity, gender, and
presence of any other medical condition was obtained
at baseline. At baseline and at 9 year follow-up, these pa-
tients were given standardised questionnaires for as-
sessing the disability and pain. Disability was estimated
by ODI comprising 10 questions about pain related dis-
ability, each having six verbal response alternatives. The
sum of the response score was calculated and presented
as percentage where 0% represents no pain and disabi-
lity, and 100% represents the worst possible pain and
disability [33]. LBP intensity was scored on three vertical
visual analog scales (VAS), ranging from 0 (no pain) to
100 (worst pain imaginable). Patients scored their ma-
ximum pain, minimum pain and current pain the last
week, respectively. The mean of these three measure-
ments was calculated [34].
The outcome variables were the change in ODI and
VAS scores at follow-up (post treatment value – pre
treatment value).
Radiological assessment of disc degeneration
Disc degeneration in all patients was assessed for levels
L1-S1 by plain radiography. MRI (N = 65) and Com-
puted Tomography scanning [CT] (N = 14) were also
used, but not in all patients. MRI signal changes in lum-
bar discs were graded into six patterns [35]. Pattern 1:
Thickened cleft but normal disc signal intensity and
height with no protrusion; Pattern 2: Similar to pattern
1 with slight overall reduction in disc signal intensity;
Pattern 3: Normal disc signal intensity, height and cleft
with small protrusion; Pattern 4: Disc signal intensity
was further reduced, mild narrowing of the disc space,
cleft present with definite protrusion of the disc; Pattern5: Marked reduction in disc signal intensity and height
with protrusion and cleft poorly defined; Pattern 6: Mi-
nimal or lost disc signal with marked resorption and
protrusion of the disc with no cleft.
MRI changes were dichotomized into moderate if
assessed to be of pattern 1-4; and severe if the pattern was
5 or 6. Degeneration on CT scans was classified moderate
if disc height was considered to be < 50% of the normal
height and severe if disc height was reduced > 50%.DNA extraction
Genomic DNA from 89 patients was extracted from
approx 9 ml of venous blood by salting out method [36].
From all 93 patients, DNA was extracted from approx
2 ml of saliva using a collection kit, purifier and proto-
col from DNA genotek (Kanata, Ontario Canada). This
means that in four patients DNA was extracted from sa-
liva only. Both blood samples and saliva were collected
at the Hospital facility. DNA quality and concentration
were measured on a DNA spectrophotometer (ND-1000,
NanoDrop, Wilmington USA).
For the 89 patients, we compared the purity and total
DNA yield (μg) from blood and saliva samples. The
amount of DNA (μg) obtained given as mean [SEM]
from blood sample was 229.3 [8.0] and from saliva, it
was 339.3 [21.6] respectively (Figure 1). Purity of the
DNA was assessed by the ratio of absorbance at 260 nm
and 280 nm (A260/280), and values ≥ 1.8 indicate a pure
DNA. The mean A260/280 ratio for the blood sample
was 1.86 [0.001] and 1.94 [0.007] for saliva, respectively.
There were no drop out for DNA samples extracted
from blood, but one drop out from a DNA sample
extracted from saliva (A260/280 < 1.8). For 48 patients,
DNA from blood as well as saliva was genotyped to-
gether, and genotype success rate of DNA from both
sources was comparable for the tested SNPs.Selection of single-nucleotide polymorphisms and
genotyping
A total of eight single-nucleotide polymorphisms (SNPs)
from five different inflammatory and matrix degrading
genes were tested on the basis of previously reported as-
sociations with disc degeneration and their established
role in pain related pathways. These included SNPs from
interleukin genes (IL1A, IL18R1, and IL18RAP), matrix
metalloprotease-3 gene (MMP3), and cyclooxygenase-2
gene (COX2).
Genotyping for the SNPs was performed by Sequenom™
system, using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry at the
Centre for interactive genetics; Cigene, Norwegian Univer-



















Figure 1 Scattergram of DNA yield (μg) in 89 blood and saliva samples. Scattergram of total DNA yield (μg) in 89 blood and saliva samples.
The dashed line represents the mean value and continuous lines denote standard error of mean (SEM).
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Hardy-Weinberg equilibrium, pair wise linkage disequili-
brium (LD), genotype success rate and minor allele fre-
quency were calculated using the statistical programme
Haploview version 4.2 [37]. The cut off value for diver-
gence from Hardy-Weinberg equilibrium was (p ≥ 0.001).
Linear and logistic regression analysis was performed
for assessing the effect of each individual SNP on the re-
gression of degeneration, number of segments involved,
ODI and LBP change as dependent variables, along with
controlling for the covariates age, sex and fusion. Asso-
ciation was tested using three different types of genetic
models on the same data set. A recessive genetic model,
assuming that severe degeneration and change in post
treatment pain scores was increased / decreased when
having two copies of a specific allele compared to having
only one or zero copies of the specific allele. The mean
difference in pain and disability score (β) between pa-
tients having two copies and those having one or zero
copies was estimated in regression analysis. In the ad-
ditive model, we assumed that the change in the pro-
gression and pain scores was increased two fold by
possessing two copies of the specific allele, compared to
having a single copy. For the dominant genetic model
we pre specified the dominant allele to be a risk allele
and carriers were compared with the opposite non-risk
homozygous alleles [38]. A p-value ≤ 0.05 was consi-
dered statistically significant. We consider our study to
be an explorative genetic association study, and there-
fore the p-values were not formally corrected for mul-
tiple testing.Association between the common haplotypes of the
SNPs with frequency > 0.02 and severity of degeneration,
numbers of segments involved, pain and disability, along
with effect of the covariates was tested using the R package
Haplostats [39]. The estimated frequencies and regression
coefficients were computed by the function haplo.glm
using an additive model. The reference haplotype was se-
lected to be the most frequent haplotype as a baseline for
linear regression by the software.
Results
The genotype success rates for the eight SNPs were
100% and minor allele frequencies observed for the
tested SNPs in the present population were comparable
to what has been reported for European Hap Map sam-
ples (Table 1). No divergence from Hardy-Weinberg
equilibrium observed for any of the tested markers.
SNP associations with pain and disability outcome
Association analysis of individual SNPs with the 9 years
post treatment change in pain and disability scores using a
recessive genetic model among 93 patients, revealed sta-
tistically significant associations between post treatment
improvement in disability (ODI change) and two SNPs
from IL18RAP gene, rs1420106 and rs917997 (p = 0.02)
(Table 2). The alleles at these two polymorphisms
rs1420106-A and rs917997-T were in strong LD (D'=1 and
r2=0.9) and hence represented the same association. A sig-
nificant association (p = 0.03) was also observed between
post treatment improvement in pain and a polymorphism
(rs72520913) of the MMP3 gene (Table 2). Our study had
Table 1 Overview of the selected SNPs and their genotyping performance
SNP* Gene HWE** p-value GRS %† Alleles‡ MAF§ cases MAF ∞ reported
rs2071375 IL1A 1.0 100 T/C 0.25 0.21
rs2287037 IL18R1 0.73 100 T/C 0.32 0.39
rs1420100 IL18RAP 1.0 100 A/C 0.50 0.51
rs1420106 IL18RAP 0.7 100 A/G 0.25 0.21
rs917997 IL18RAP 1.0 100 T/C 0.27 0.20
rs5277 COX2 0.81 100 G/C 0.19 0.21
rs4140564 COX2 1.0 100 G/A 0.05 0.08
rs72520913 MMP3 0.09 100 A/C 0.50 Not reported
* Single nucleotide polymorphism; ** Hardy-Weinberg equilibrium; † Genotype success rate;
‡ Minor/Major alleles; § Minor allele frequency; ∞ MAF HapMap-CEU European.
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VAS LBP with a significance level of 0.05 for the associa-
ted single nucleotide polymorphisms (SNPs).
No significant effect of the other covariates included
in the models (age, gender and fusion) was observed.
Table 3 describes the study population characteristics
and values for post treatment disability and pain reduc-
tion according to the genotype for associated SNPs. For
IL18RAP SNP rs917997, we observed that improvement in
disability was reduced among T/T homozygotes (N = 7,
mean [SD] – 2.0 [17.8]) compared to the C/C homozygotes
(N = 50, Mean [SD] – 21.5 [19.6]), and T/C heterozygotes
(N = 36, mean [SD] – 21.4 [21.5]). The improvement in
disability for the other associated IL18RAP SNP rs1420106
was also the less among A/A homozygotes (N = 7, mean
[SD] – 2.0 [17.8]), where as larger improvement was
observed for A/G heterozygotes (N = 33, mean [SD] –
23.8 [20.8]) and G/G homozygotes (N = 53, mean [SD] –
20.0 [20.8]).
Similarly, lower reduction in pain was observed among
patients who were homozygous A/A for MMP3 SNP
rs72520913 (N = 18, mean [SD] – 10.8 [18.5]) compared
to the heterozygous A/C (N = 56, mean [SD] – 28.7
[33.2]) and homozygous C/C (N = 19, mean [SD] – 25.5
[26.2]) genotypes.Table 2 Association analysis of inflammatory and matrix deg
VAS LBP change in 93 patients with LDD and LBP
ODI
SNP* Gene Recessive genotype Mean difference (β) †
rs2071375 IL1A T/T 8.8 (-8.3 - 26
rs2287037 IL18R1 T/T 6.8 (-8.6 – 22
rs1420100 IL18RAP A/A 6.1 (-4 – 16.
rs1420106 IL18RAP A/A 19.4 (3.9 - 3
rs917997 IL18RAP T/T 19.4 (3.9 - 3
rs5277 COX2§ G/G 15.0 (-5.8 – 3
rs72520913 MMP3 A/A 5.0 (-5.7 – 15
* Single nucleotide polymorphism; † mean difference in pain and disability scores f
§ COX2 SNP rs4140564 was left out of the analysis due to no G/G genotype in theAdditive and dominant genetic model association tes-
ting revealed no statistically significant associations bet-
ween post treatment ODI and VAS LBP change and any
of the tested markers.Associations with severity of degeneration (MRI and CT)
and number of discs involved
We observed an association of the IL18RAP polymor-
phism rs1420100 with severe degeneration (p = 0.05; odds
ratio = 3.9; 95% CI = 1.1-19.3) compared to moderate, and
with degeneration of more than one disc compared to one
(p = 0.02; odds ratio = 4.1; 95% CI = 1.3-14.0), using a
dominant model. MMP3 polymorphism rs72520913
was found to be associated with severe degeneration
(p = 0.006; odds ratio = 3.5; 95% CI = 1.5-9.4) using the
additive model but no associations were observed for the
recessive genetic model.
Haplotype association analysis for severity of
degeneration and treatment outcome
The five SNPs (rs2071375, rs2287037, rs1420100,
rs1420106, rs917997) from the biologically similar pro-
inflammatory neighbouring genes located on chromo-
some 2 (IL1A, IL18R1, IL18RAP) were in LD and fourrading gene polymorphisms with 9 years ODI change and
change VAS LBP change
(95% CI)∞ p value Mean difference (β) (95% CI) p value
) 0.31 11.3 (-11.3 - 33.9) 0.32
.2) 0.38 11.0 (-9.3 - 11) 0.29
2) 0.23 5.1 (-8.3 – 18.5) 0.45
5) 0.02 18.4 (-2.5 – 39.3) 0.08
5) 0.02 18.4 (-2.5 – 39.3) 0.08
5.8) 0.16 24.4 (-2.8 – 51.6) 0.08
.7) 0.36 15.6 (1.8 – 29.4) 0.03
or two rare alleles; ∞ 95% confidence interval.
cohort.
Table 3 Characteristics of the patients (N=93) carrying different genotypes for the associated SNPs
IL18RAP (rs1420106) IL18RAP (rs917997) MMP3 (rs72520913)
Genotype A/A A/G G/G T/T C/T C/C A/A A/C C/C
Number of Patients 7 33 53 7 36 50 18 56 19
Males / Females 2/5 10/23 23/30 2/5 11/25 22/28 8/10 19/37 8/11
Age at follow-up 49.9 [9.1] 49.3 [12.9] 53.8 [7.3] 49.9 [9.1] 49.8 [8.2] 53.7 [7.4] 51.6 [8.7] 53.2 [6.7] 48.4 [10.0]
Mean [SD]
Fusion/cognitive 5/2 23/10 32/21 5/2 24/12 31/19 10/8 39/17 11/8
Baseline ODI 43.1 [8.9] 47.6 [12.9] 42.0 [9.6] 43.1 [8.9] 46.5 [18.2] 42.5 [9.6] 40.3 [10.0] 45.1 [11.0] 44.6 [11.8]
Mean [SD]
Follow-up ODI 41.1 [20.6] 23.9 [18.5] 21.9 [17.6] 41.1 [20.6] 25.1 [18.2] 21.0 [17.6] 25.2 [14.1] 24.6 [19.6] 21.3 [19.8]
Mean [SD]
ODI change - 2 [17.8] - 23.8 [20.8] - 20.0 [20.8] - 2 [17.8] - 21.4 [21.5] - 21.5 [19.6] - 15.2 [16.3] - 20.4 [22.0] - 23.3 [20.8]
Mean [SD]
Baseline VAS LBP 56.5 [14.2] 64.5 [13.3] 61.9 [13.7] 56.5 [14.2] 63.7 [13.1] 62.3 [14.0] 59.5 [11.7] 62.5 [13.5] 64.7 [15.9]
Mean [SD]
Follow-up VAS LBP 48.8 [23.2] 38.4 [25.3] 36.0 [25.8] 48.8 [23.2] 39.1 [24.5] 35.3 [26.3] 48.7 [20.0] 33.8 [25.6] 39.2 [27.5]
Mean [SD]
VAS LBP change - 7.7 [24.3] - 26.1 [25.8] - 25.9 [32.9] - 7.7 [24.3] - 24.6 [25.3] - 27.0 [33.5] - 10.8 [18.5] - 28.7 [33.2] - 25.5 [26.2]
Mean [SD]
Worst possible score for ODI and VAS LBP was 100.
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types (Table 4).
Haplotype association analysis revealed significant as-
sociations for the haplotype T-C-C-A-T with improve-
ment in disability (p = 0.02; mean difference = 20.0; 95%
CI = 3.0-37.0) and reduction in pain (p = 0.04; mean dif-
ference = 24.0; 95% CI = 1.4-46.5) at 9 year follow-up.
No association of any haplotype of chromosome 2
markers was observed with the severity of degeneration
and number of degenerated discs.
Discussion
Several studies have previously reported the association
of inflammatory and matrix degrading genes with LDDTable 4 Estimated haplotype frequencies for SNPs at
IL1A, IL18R1 and IL18RAP chromosome 2 in 93 LDD
patients with LBP
rs2071375 rs2287037 rs1420100 rs1420106 rs917997 Frequency
%
C C C A T 21.2
C T A G C 7.0
C T C G C 16.2
T C A G C 13.6
T C C A T 4.0
T T C G C 6.9
*C C A G C 29.4
* Reference haplotype (most frequent).[9,10,14], and findings of the present study confirms that
some of these genes influence the radiographic degene-
ration of the lumbar disc. The novelty of the present
study is that it also highlights the influence of these va-
riants on pain and disability at long term in patients
treated with spinal fusion or cognitive intervention and
exercises for CLBP.
This study observed associations of IL18RAP polymorph-
ism rs1420100 and MMP3 polymorphism rs72520913 with
severe degeneration and for rs1420100 also with more than
one degenerated disc. Interestingly two other polymor-
phisms of IL18RAP, rs917997 and rs1420106, showed asso-
ciation with improvement in disability. Furthermore the
MMP3 polymorphism, rs72520913, was observed to be as-
sociated with reduction in pain.
The associations between IL18RAP polymorphism
rs1420100 with severity of degeneration and the number
of degenerated discs are in line with results from a pre-
vious study by Videman et al. They were the first to
identify an association of this SNP of IL18RAP gene with
LDD [10]. In their study of 588 monozygotic and dizyg-
otic male twins from the Finish population, they
reported a significant association with disc desiccation at
both upper and lower lumbar levels, which is considered
to be an earlier stage of degenerative process. They did
not find an association with disc height narrowing or
bulging. In contrast, we only assessed the lower lumbar
segments (L4-L5 and L5-S1). These are usually more
prone to severe degeneration and our association was
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LBP and were considered for lumbar fusion. Although
our findings strengthen the evidence in support of previ-
ously reported association of IL18RAP gene variant with
radiographic lumbar disc degeneration, we could not
rule out that these findings could be by chance. The
small sample size and no correction for multiple testing,
does not allow drawing firm conclusions.
IL18RAP is a subunit of IL18 receptor along with
IL18R1 [40] and is essential for IL18 signal transduction
and ligand binding affinity. IL18R mediated activation of
T cells and natural killer cells results in secretion of
interferon gamma (IFN-γ), which induce macrophages
to secrete cytokines TNF-α and IL-1, which are eventu-
ally involved in increased matrix degradation, by produc-
tion of cytokines and proteases. These have been found
to be secreted by the cells of degenerated and herniated
discs [41-43]. This sheds light on a putative connection
between inflammation and degeneration and a possible
pathway for back pain.
Interestingly in the present study, two other tested
IL18RAP polymorphisms, rs917997 and rs1420106, did
not display association with severity of degeneration, but
with reduction in disability. The reduction was less pro-
nounced among T/T genotypes at rs917997 compared to
C/C and C/T indicating that carrying even one copy of
T allele was associated with reduced improvement in
disability. Similar lower reduction appeared to be attri-
buted to A allele for rs1420106 where less improvement
was observed with A/A compared to the G/G and A/G ge-
notypes. The alleles at these polymorphisms rs1420106-A
and rs917997-T were in strong LD and both revealed si-
milar association with improvement in disability. On the
other hand, the alleles rs1420100-A and rs917997-T or
rs1420106-A, were never carried on the same haplotype,
but were in complete negative LD (D' = - 1). Therefore we
speculate that different genetic variants at the same gene,
i.e. IL18RAP, affect both the severity of degeneration and
improvement in outcome. The polymorphisms rs1420106
and rs917997 were found to be associated with disc des-
iccation in the study by Videman et al, but no association
of these polymorphisms was observed with severity of de-
generation in the present study. The SNP rs917997 has
previously been reported to be associated with differen-
tial expression of IL18RAP gene in coeliac disease pa-
tients [44].
We observed that a haplotype T-C-C-A-T spanning the
IL1A, IL18R1 and IL18RAP genes located on chromo-
some 2, revealed association with improvements in pain
and disability. IL-18 is a member of the IL-1 family of
cytokines. These are related in terms of structure, recep-
tor family and signal transduction pathways [45] and
both are located on chromosome 2. Based on these simi-
larities, we considered the IL1A rs2071375 along withIL18 receptor polymorphisms when testing the associ-
ation of haplotypes.
The association of MMP3 SNP rs72520913 with severe
degeneration is in agreement with previously reported
associations with disc degeneration [9]. This SNP has
been reported to regulate the MMP3 gene expression
where the 5A allele possesses twice the promoter activity
compared to the 6A allele [25]. A study involving elderly
patients found the 5A/5A genotype to be associated with
presence of osteophytes, narrowing of discs and end
plate sclerosis [15]. Another study evaluated the inter-
action between this polymorphism and whole body vi-
bration (gene-environment interaction) and revealed
susceptibility between the 5A allele and LDD [16]. To-
gether with IL1A it has been reported to be associated
with type II Modic changes [13]. In vitro studies have
also highlighted the role of MMP3 in intervertebral disc
degeneration through matrix degradation [46]. Our find-
ing supports the role of variant(s) in promoter region of
MMP3 gene in LDD, and based on the fact that such
polymorphisms may enhance the MMP3 expression, we
speculate that they may ultimately disturb the balance of
ECM of the lumbar disc. Contrary to this, the associ-
ation of the same polymorphism with improvement in
pain after treatment, is difficult to understand, but in
line with other studies that have reported a low correl-
ation between clinical and radiographic outcome [12,32].
The inflammatory genes tested in the present study
are interestingly also involved in the modulation of pain.
They regulate the production of cytokines that may con-
tribute to LBP by inducing growth of nerve and vascular
elements [47,48]. IL18 induced synthesis of tumor nec-
rosis factor-alpha (TNFα) has also been proposed to play
a role in discogenic pain [49]. MMP3 and IL1A have been
associated with neuropathic pain and sensitization of
nocireceptors [18,24].
Our finding of a higher yield of DNA extracted from
saliva compared to blood was similar to Mitsouras et al
report that DNA yield from saliva was superior to blood
and buccal swabs [50]. In accordance with our finding
that saliva DNA was of high quality, a study had pre-
viously reported the saliva DNA extracted using similar
kits and methods as ours, to be of high quality [51].
Other studies have reported an equal or lower DNA
yield from saliva compared to the blood [28,52].
The main strengths of the present study include long
term follow up of patients, a high genotype success rate
alongside homogeneity of the sample population (all sub-
jects were of homogenous Norwegian origin) and testing
of polymorphisms from genes that have previously been
reported to be involved in both degeneration and pain
modulation.
Limitations were small sample size, no testing for mul-
tiple correction, dichotomy of images of degeneration
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classification, inclusion of patients with only 1-2 levels
involved rather than multi level degeneration and testing
by three genetic models on the same data. Furthermore,
we have only tested one or few variants from each of
these inflammatory genes, thus we could have missed
the involvement of genetic variation at each tested gene.
Despite these limitations, our study gives valuable repli-
cation of previous findings, support the importance of
variation at inflammatory and matrix degrading genes in
the degeneration process and LBP and provide hypothesis
for future studies. Replication of these results in larger
study populations is important for strengthening conclu-
sions from the present study.
Conclusions
This study suggests a role of variation at inflammatory
and matrix degrading genes in severity of LDD and pain
and disability outcome.
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